We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vorinostat and Palliative Radiotherapy (PRAVO)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00455351
First Posted: April 3, 2007
Last Update Posted: July 22, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Oslo University Hospital
April 2, 2007
April 3, 2007
July 22, 2011
February 2007
Not Provided
DLT [ Time Frame: continously ]
Not Provided
Complete list of historical versions of study NCT00455351 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vorinostat and Palliative Radiotherapy
Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Phase I study. Side-effects when combined with standard palliative radiotherapy.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Pelvic Cancer
  • Radiotherapy
Drug: Vorinostat
Increasing dosing, phase I
Experimental: A I
Study drug
Intervention: Drug: Vorinostat

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
August 2009
Not Provided

Inclusion Criteria:

  • Pelvic malignancy
  • Palliative radiation treatment planed
  • ECOG <3
  • Age>18 years

Exclusion Criteria:

  • Previous pelvic radiotherapy
  • Uncontrolled diarrhea
  • Insulin-dependent diabetes mellitus
  • BMI<18.5
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
 
NCT00455351
EudraCTnumber 2006-003631-76
No
Not Provided
Not Provided
Svein Dueland (PI), Rikshospitalet-Radiumhospitalet HF
Oslo University Hospital
Not Provided
Study Director: Sigbjørn Smeland, MD,PhD Norwegian Radium Hospital
Oslo University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top